Laccase/caffeic acid-catalyzed crosslinking coupled with galactomannan alters the conformational structure of OVA and alleviates Th2-mediated allergic asthma

Ovalbumin (OVA) is the major allergenic protein that can induce T helper 2 (Th2)-allergic reactions for which current treatment options are inadequate. In this study, we developed a polymerized hypoallergenic OVA product via laccase/caffeic acid (Lac/CA)-catalyzed crosslinking in conjunction with galactomannan (Man). The formation of high molecular weight crosslinked polymers and IgG-binding were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) western blotting. study indicated Lac/CA-catalyzed plus Man conjugation substantially altered secondary tertiary structures along variation surface hydrophobicity. Gastrointestinal digestion stability assay exhibited less resistance simulated gastric fluid (SGF) intestinal (SIF). Mouse model Lac-Man/OVA ameliorated eosinophilic airway inflammatory response efficiently downregulated expression Th2-related cytokines (IL-4, IL-5, IL-13), upregulated IFN-γ IL-10 expression. Stimulation bone marrow-derived dendritic cells suppressed phenotypic maturation markers (CD80, CD86) MHC class II molecules, levels proinflammatory cytokines. knowledge obtained present offers an effective way to acquire have therapeutic effect alleviating OVA-induced allergic asthma.